109 related articles for article (PubMed ID: 24105355)
1. Thalidomide-induced hemorrhagic rash in a patient with myelofibrosis and delta-granule storage pool disease.
Taj A; Abbi K; Skeel RT
Am J Ther; 2015; 22(1):e6-7. PubMed ID: 24105355
[TBL] [Abstract][Full Text] [Related]
2. [Advances in thalidomide therapy for idiopathic myelofibrosis].
Song L; Chen JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):651-3. PubMed ID: 19968089
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-induced morbilliform rash: diagnosis and continuation of therapy, premedicated with methylprednisolone.
Nijsten T; Meuleman L; Schroyens W; Lambert J
Dermatology; 2002; 204(4):365-7. PubMed ID: 12077549
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide induced acute worsening of Parkinson's disease.
Crystal SC; Leonidas J; Jakubowski A; Di Rocco A
Mov Disord; 2009 Sep; 24(12):1863-4. PubMed ID: 19606491
[No Abstract] [Full Text] [Related]
6. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for treatment of autoimmune acquired platelet function disorders: description of two cases of acquired Glanzmann thrombasthenia and one case of acquired delta storage pool disease.
Alberelli MA; Bacci M; Marchetti M; Ferrazzi P; Dragani A; Gamba S; Landolfi R; Falanga A; Lodigiani C; De Candia E
Br J Haematol; 2019 Dec; 187(5):e87-e91. PubMed ID: 31612461
[No Abstract] [Full Text] [Related]
10. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
11. Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme.
Varma K; Finlay AY
Br J Dermatol; 2006 Apr; 154(4):789-90. PubMed ID: 16536837
[No Abstract] [Full Text] [Related]
12. [Thalidomide therapy of cutaneous lupus erythematosus].
Bohmeyer J; Achenbach A; Westenberger M; Stadler R
Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
[TBL] [Abstract][Full Text] [Related]
13. [Potential side effects of thalidomide].
Rev Prat; 2006 Jan; 56(1):52. PubMed ID: 16548249
[No Abstract] [Full Text] [Related]
14. Exacerbation of psoriasis by thalidomide in Behçet's syndrome.
Dobson CM; Parslew RA
Br J Dermatol; 2003 Aug; 149(2):432-3. PubMed ID: 12932265
[No Abstract] [Full Text] [Related]
15. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
17. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
19. [Weight gain during treatment with thalidomide: a case report].
Comte H; Béné J; Auffret M; Gautier S; Salle-Staumont D
Therapie; 2014; 69(5):457-9. PubMed ID: 25285366
[TBL] [Abstract][Full Text] [Related]
20. Low-dose thalidomide in myelofibrosis.
Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
